Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T16:50:28.455Z.
Consensus retrieved: 2026-10-06T08:44:49.622Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T16:50:28.455Z.
Quote observation: 2026-10-06T16:50:04.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: ce14650c18fa49a41504767bbd6ec089d5034b69e4d808542ce8aeb5b63776d1
Forward PE Ratio (N/A) = Dated Quote Price ($1.13) / Consensus Forward EPS ($-0.56)
FORWARD PE RATIO
N/A
ALX Oncology Holdings Inc.
Market Cap
$152.06M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| ALX Oncology Holdings Inc. (ALXO) | $152.06M | N/A |
| Codexis, Inc. (CDXS)vs › | $151.66M | N/A |
| Cardiol Therapeutics Inc. (CRDL)vs › | $151.58M | N/A |
| Anavex Life Sciences Corp. (AVXL)vs › | $149.20M | N/A |
| NervGen Pharma Corp. Common stock (NGEN)vs › | $148.36M | N/A |
| LifeMD, Inc. (LFMDP)vs › | $148.31M | N/A |
| Jyong Biotech Ltd. Ordinary Shares (MENS)vs › | $155.86M | N/A |
| Neuronetics, Inc. (STIM)vs › | $156.53M | N/A |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $146.98M | N/A |
| Inogen, Inc. (INGN)vs › | $157.71M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $1.13, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-0.56 | $-0.60 – $-0.52 | 3 | n/m |
| 2027-12-31 | $-0.55 | $-0.65 – $-0.49 | 5 | n/m |
| 2028-12-31 | $-0.52 | $-0.73 – $-0.36 | 6 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
